Abstract
Tirzepatide (Mounjaro) is a dual GLP‐1/GIP receptor agonist for the treatment of type 2 diabetes in adults. This article discusses its administration, clinical trial efficacy and adverse effects.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have